COMP <GO>
UAMY vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
United States Antimony Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: UAMY 2
— TMO 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $3.16 (-2.17%) • MKT CAP: $473.0M
roic
-6.00%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UAMY VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UAMY | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -6.00% | 9.30% | -15.30 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.93% | 2.40% | -10.33 | TMO | /fcf-yield <GO> |
| Operating Margin | -21.50% | 17.40% | -38.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | -11.10% | 15.10% | -26.20 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 162.80% | 3.90% | +158.90 | UAMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 21.89 | 4.50 | +17.39 | UAMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.6 | 62.9 | -26.30 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $473.0M | $262.22B | -$261.74B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UAMY REV | TMO REV | UAMY GROSS % | TMO GROSS % | UAMY FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.3M | $44.56B | 25.2% | — | -$37.5M | $6.29B |
| FY 2024 | $14.9M | $42.88B | 23.2% | — | $1.8M | $7.27B |
| FY 2023 | $8.7M | $42.86B | — | — | -$4.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UAMY // BETA —
TMO // BETA 0.94